Neoadjuvant HER2+ Articles | Page 3

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers
Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.
1-Year of Adjuvant Trastuzumab Remains Standard in HER2+ Breast Cancer
The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.
Trastuzumab Disappoints in HER2-low Patient Cohort
A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.
Expert Emphasizes Importance of Neoadjuvant Therapy in HER2+ Breast Cancer
Patrick Borgen, MD, discusses the importance of neoadjuvant therapy in the treatment of patients with HER2-positive breast cancer.
Adjuvant Treatment Evolving for HER2+ Breast Cancer
Sara M. Tolaney, MD, discusses the state of adjuvant treatment for patients with HER2-positive breast cancer.
Expert Highlights Expanding Options for HER2+ Breast Cancer
Lajos Pusztai, MD, discusses neoadjuvant and adjuvant treatment decisions for patients with HER2-positive breast cancer, as well as the potential of immunotherapy in the metastatic setting.
Neoadjuvant Treatment Evolving in HER2-Positive Breast Cancer
Elizabeth A. Mittendorf, MD, PhD, discusses the evolving neoadjuvant treatment landscape and other developments in the field of HER2-postive breast cancer.
Neratinib Offers Hope in Treatment of CNS Metastases in HER2+ Breast Cancer
Rachel A. Freedman, MD, discusses treating patients with HER2-positive breast cancer who develop CNS metastases, and the promise that neratinib holds in this patient population.
Hamilton Highlights Progress in HER2-Positive Breast Cancer
Erika P. Hamilton, MD, discusses the current treatment landscape for patients with HER2-positive breast cancer.
FDA Grants Pertuzumab Priority Review for HER2+ Early Breast Cancer
The FDA has granted a priority review to a supplemental biologics license application for pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.
Publication Bottom Border
Border Publication